U.S. Stocks in Motion | Nvidia-backed AI drug discovery company Iambic Therapeutics (IAM.US) debuts on Nasdaq, rises over 11% after the open.

Zhitong Finance APP has learned that on Thursday, AI drug discovery company Iambic Therapeutics (IAM.US), in which Nvidia holds a stake, listed on Nasdaq. As of press time, the stock rose more than 11% to $17.77, triggering an exchange circuit breaker. The IPO price was $16. Iambic Therapeutics is a clinical-stage biotechnology company that combines proprietary AI models with automated high-throughput chemistry and biology to design small molecule drugs. The platform operates a closed-loop process: its models propose compound designs, robotic laboratories synthesize and test hundreds of compounds per project each week, and the resulting data are used to retrain the models. Its lead candidate, IAM1363, is a selective, blood-brain barrier-penetrant HER2 inhibitor that is in a Phase 1/1b clinical trial for HER2-altered solid tumors and could potentially begin a registrational trial as early as 2027; two other preclinical programs targeting KIF18A and CDK2/4 are planned for IND submissions in the fourth quarter. To date, Iambic Therapeutics has generated revenue through collaborations with companies such as AbbVie (ABBV.US), Takeda Pharmaceutical (TAK.US), and Bayer (BAYRY.US).